Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

March 13, 2024

https://www.globenewswire.com/news-release/2024/03/13/2845822/0/en/Spero-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2023-Operating-Results-and-Provides-a-Business-Update.html

CAMBRIDGE, Mass., March 13, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.